NRIP3基因高表达抑制淋巴结阴性乳腺癌转移的研究

Overexpression of NRIP3 gene inhibited metastasis in lymph node negative breast cancer

目的探讨核受体相互作用蛋白(NRIP3)在乳腺癌组织中的表达及与淋巴结阴性乳腺癌无远处转移生存的关系。方法利用BRB-Array Tools软件分析165例乳腺癌芯片中NRIP3基因表达水平,Kaplan-Meier法计算不同表达水平的无远处转移生存率,并进行Log-rank检验;应用Cox比例风险回归模型行多因素分析。结果 NRIP3基因低、中、高表达组中位无远处转移生存期(DMFS)分别为(3 980±331)d、(4 391±246)d、(4 518±147)d,Logrank检验生存曲线差异有统计学意义(χ2=7.847,P<0.05),多因素Cox模型分析显示,NRIP3基因高表达是乳腺癌远处转移独立的保护因素(P<0.01,Exp(B)=0.387)。雌激素受体(ER)阳性患者中NRIP3高表达率为41.2%(42/102),ER阴性患者中NRIP3高表达率为20.6%(13/63),差异有统计学意义(χ2=7.427,P<0.05);ER阳性的乳腺癌患者中,低表达NRIP3基因组的DMFS为(4 191±366)d,明显低于中表达组和高表达组(χ2=7.268,P<0.05),在ER阴性的乳腺癌患者中差异无统计学意义(χ2=0.524,P>0.05)。结论 NRIP3基因高表达可抑制淋巴结阴性乳腺癌发生远处转移,其发挥作用与ER阳性表达以及可能的内分泌治疗关系值得进一步研究。

Objective To investigate the relationship between expressions of nuclear receptor interacting protein 3（NRIP3） and distant metastasis-free survival（DMFS） in lymph node negative breast cancer.Methods Affymetrix microarray datas of 165 breast cancer patients were analyzed by BRB-Array Tools to evaluate the NRIP3 expression.Follow-up data were handled by Kaplan-Meier survival analysis and multivariate Cox regression analysis.Results The median DMFS of the high,medium and low NRIP3 expression groups was 3 980±331 days,4 391±246 days and 4 518±147 days respectively.Multivariate Cox regression analysis showed that NRIP3 was the independent prognostic marker for DMFS（P0.01,Exp（B）=0.387）.NRIP3 overexpression rate was 41.2%（42/102） and 0.6%（13/63） in ER positive and negative breast cancer patients respectively,and the difference between the two groups was significant.DMFS of the low NRIP3 expression group was significantly lower than the one of the medium and high expression groups in ER positive patients（χ2=7.268,P0.05）.But there was no difference of DMFS among the three groups in ER negative breast cancers patients（χ2=0.524,P0.05）.Conclusion Over-expression of NRIP3 can inhibit metastasis in lymph node negative breast cancer patients,and its relationship with ER expression and endocrine therapy deserve further study.